Sglt2 Inhibitors Are Associated With Reduced Cardiovascular Disease For Patients With Type 2 Diabetes | Latest News RSS feed

Sglt2 Inhibitors Are Associated With Reduced Cardiovascular Disease For Patients With Type 2 Diabetes - Latest News

SGLT2 Inhibitors are Associated with Reduced Cardiovascular Disease for Patients with Type 2 Diabetes

SAN DIEGO, June 13, 2017 /PRNewswire-USNewswire/ -- A new class of medication, known as sodium-glucose transporter-2 (SGLT2) inhibitors, is associated with lower rates of death and hospitalization for ... read more

Lixisenatide Renal Benefit in Diabetes With Macroalbuminuria

BERLIN — The injectable glucagon-like peptide (GLP-1) agonist lixisenatide (Lyxumia, Sanofi) may protect patients with type 2 diabetes who have cardiovascular disease ... inhibitors, and sodium glucos... read more

Positive Results for Empagliflozin in Type 1 Diabetes Trials

Empagliflozin (Jardiance; Boehringer Ingelheim and Lilly), a sodium-glucose co-transporter 2 (SGLT2) inhibitor ... with type 2 diabetes mellitus (T2DM) and to reduce the risk of cardiovascular (CV) de... read more

Looking for another news?

One class of drug used to treat type 2 diabetes may not reduce the risk of death when compared with placebo

However the DPP-4 inhibitor drugs were not associated with a reduced risk of mortality compared to people taking placebo or no treatment at all. Furthermore, SGLT-2 inhibitor ... "Patients with type 2 ... read more

HARMONY: Albiglutide reduces CV risk in adults with type 2 diabetes, CVD

“The bigger picture is that if you want to reduce the risk of non-fatal and fatal CV events in patients with type 2 diabetes and established CV disease, you should consider a SGLT-2 inhibitor ... and ... read more

AMPK Activator O304 A Novel Potential Treatment for Diabetic Kidney Disease

Globally ~40% of type 2 diabetes ... vascular system to reduce hyperfiltration. SGLT2 inhibitors are recently introduced anti-hyperglycaemic agents that show improved renal outcome in T2D patients wit... read more

Antisense Lp(a) Agent; Overdose Drug with AEDs; Mixed CV Results for T2D Drug

The SGLT2 inhibitor dapagliflozin (Farxiga) failed to reduce major cardiovascular events compared with placebo in the DECLARE-TIMI-58 cardiovascular outcomes trial in type 2 diabetes but ... test to p... read more

AstraZeneca Looks To Prove Itself In The Type 2 Diabetes Market

AstraZeneca announced positive results for type 2 diabetes patients with renal impairment who were treated with its SGLT2 inhibitor FARXIGA ... since it has shown to reduce the risk of advance renal i... read more

New data from landmark CVD-REAL study of patients with type-2 diabetes confirms CV benefits associated with SGLT-2 inhibitors

Dapagliflozin is not indicated to reduce ... Events in Type 2 Diabetes. New England Journal of Medicine. 2017. DOI: 10.1056/NEJMoa1611925. 9.Kosiborod M, et al. Lower risk of heart failure and death i... read more

Certain Patients with Type 2 Diabetes Less Likely to Suffer Heart Failure While Taking New Class of Antidiabetic Drug

INDIANAPOLIS--(BUSINESS WIRE)--Seniors with type 2 diabetes ... Disease Control and Prevention, and our finding is intriguing in light of the overwhelming interest around the reduction of heart failur... read more

New data shows Jardiance reduces risk of kidney disease in people with type 2 diabetes with established CV disease

New data showed Jardiance (empagliflozin) reduced the risk ... Jardiance is the only SGLT2 inhibitor associated with evidence of slowing the progression of kidney disease in adults with type 2 diabete... read more

Diabetes drug lowers risk of cardiovascular complications, kidney disease

These patients are at high risk for cardiovascular disease, which is the number one killer of people with type 2 diabetes. Liraglutide was also associated with a reduction ... The drug is a SGLT-2 inh... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us